Activated leukocyte cell adhesion molecule/CD166 as a non-invasive biomarker in women with breast cancer

IF 2.3 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Clinical Epidemiology and Global Health Pub Date : 2025-03-12 DOI:10.1016/j.cegh.2025.101974

Vemareddy Hemalatha , Shabna Roupal , Vanitharani Nagasubramanian , Bhawna Dev , S.D. Rajendran

{"title":"Activated leukocyte cell adhesion molecule/CD166 as a non-invasive biomarker in women with breast cancer","authors":"Vemareddy Hemalatha , Shabna Roupal , Vanitharani Nagasubramanian , Bhawna Dev , S.D. Rajendran","doi":"10.1016/j.cegh.2025.101974","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>ALCAM, as a non-invasive diagnostic biomarker, has the potential to revolutionize breast cancer screening by enabling early intervention and, ultimately, improving patient survival rates. This study investigated the ALCAM concentration and its diagnostic accuracy at the early stages of breast cancer (T1/T2, M0, N0).</div></div><div><h3>Methodology</h3><div>A total of 81 early stage breast cancer patients confirmed by histopathology and 81 healthy female volunteers whose breast ultrasound or mammogram were normal were included in the study. Blood, saliva, and urine samples were collected from all the included participants, centrifuged at 3000 RPM for 10 min, and the supernatant was stored at −80 °C until analyzed for ALCAM expression by using the Human ALCAM ELISA Kit.</div></div><div><h3>Results</h3><div>Receiver Operating Curves (ROC) were used to evaluate the diagnostic performance of the ALCAM biomarker in serum, saliva, and urine and were 0.947, 0.996, and 0.947, respectively. The sensitivity, specificity, and cut-off values of ALCAM expression in serum (87.7, 84, and ≥49.5), saliva (95.5, 96.3, and ≥52.5), and urine (88.89, 89.19, and ≥55) were interpreted.</div></div><div><h3>Conclusion</h3><div>ALCAM can be used to detect early breast cancers, showing better noninvasive diagnostic values. The study findings infer that ALCAM may represent a biomarker for breast cancer, which may have potential utility as a diagnostic tool as per the sensitivity and specificity values obtained.</div></div>","PeriodicalId":46404,"journal":{"name":"Clinical Epidemiology and Global Health","volume":"33 ","pages":"Article 101974"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epidemiology and Global Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213398425000636","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background

ALCAM, as a non-invasive diagnostic biomarker, has the potential to revolutionize breast cancer screening by enabling early intervention and, ultimately, improving patient survival rates. This study investigated the ALCAM concentration and its diagnostic accuracy at the early stages of breast cancer (T1/T2, M0, N0).

Methodology

A total of 81 early stage breast cancer patients confirmed by histopathology and 81 healthy female volunteers whose breast ultrasound or mammogram were normal were included in the study. Blood, saliva, and urine samples were collected from all the included participants, centrifuged at 3000 RPM for 10 min, and the supernatant was stored at −80 °C until analyzed for ALCAM expression by using the Human ALCAM ELISA Kit.

Results

Receiver Operating Curves (ROC) were used to evaluate the diagnostic performance of the ALCAM biomarker in serum, saliva, and urine and were 0.947, 0.996, and 0.947, respectively. The sensitivity, specificity, and cut-off values of ALCAM expression in serum (87.7, 84, and ≥49.5), saliva (95.5, 96.3, and ≥52.5), and urine (88.89, 89.19, and ≥55) were interpreted.

Conclusion

ALCAM can be used to detect early breast cancers, showing better noninvasive diagnostic values. The study findings infer that ALCAM may represent a biomarker for breast cancer, which may have potential utility as a diagnostic tool as per the sensitivity and specificity values obtained.

查看原文本刊更多论文

活化的白细胞粘附分子/CD166作为女性乳腺癌的非侵入性生物标志物

dalcam作为一种非侵入性诊断生物标志物，有可能通过早期干预来彻底改变乳腺癌筛查，并最终提高患者的生存率。本研究探讨乳腺癌早期ALCAM浓度（T1/T2, M0, N0）及其诊断准确性。方法选取81例经组织病理学证实的早期乳腺癌患者和81例乳腺超声或乳房x光检查正常的健康女性志愿者为研究对象。收集所有参与者的血液、唾液和尿液样本，在3000 RPM下离心10分钟，上清保存在- 80°C，直到使用Human ALCAM ELISA Kit分析ALCAM表达。结果采用受试者工作曲线（ROC）评价ALCAM生物标志物在血清、唾液和尿液中的诊断效能，ROC分别为0.947、0.996和0.947。分析ALCAM在血清（87.7、84和≥49.5）、唾液（95.5、96.3和≥52.5）和尿液（88.89、89.19和≥55）中表达的敏感性、特异性和临界值。结论alcam可用于早期乳腺癌的检测，具有较好的无创诊断价值。研究结果推断，ALCAM可能代表乳腺癌的一种生物标志物，根据所获得的敏感性和特异性值，它可能具有作为诊断工具的潜在效用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Epidemiology and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.60

自引率

7.70%

发文量

218

审稿时长

66 days

期刊介绍： Clinical Epidemiology and Global Health (CEGH) is a multidisciplinary journal and it is published four times (March, June, September, December) a year. The mandate of CEGH is to promote articles on clinical epidemiology with focus on developing countries in the context of global health. We also accept articles from other countries. It publishes original research work across all disciplines of medicine and allied sciences, related to clinical epidemiology and global health. The journal publishes Original articles, Review articles, Evidence Summaries, Letters to the Editor. All articles published in CEGH are peer-reviewed and published online for immediate access and citation.